评估 NBI-921352 作为 SCN8A-DEE 受试者辅助治疗的安全性和耐受性的扩展研究
一项前瞻性、长期、干预性、主动扩展研究,以评估 NBI-921352 作为 SCN8A 发育和癫痫性脑病综合征 (SCN8A-DEE) 受试者辅助治疗的安全性和耐受性
Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
California
-
San Francisco、California、美国、94143
- UCSF Medical Center
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- Children's National Hospital
-
-
New York
-
Rochester、New York、美国、14642
- University of Rochester
-
-
Texas
-
Fort Worth、Texas、美国、76104
- Cook Children's Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
For Participants Who Participated in NBI-921352-DEE2012:
- Written or oral pediatric assent from the participant and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and adult participants who are not capable of providing consent. Adult participant who are ≥18 years of age and capable of providing consent should sign an Informed Consent Form (ICF).
- Completed 16 weeks of treatment in Study NBI-921352-DEE2012.
- Continue to use a nocturnal alerting system or practice consistent with standards of care for the duration of the study.
- Have an adequate rescue medication regimen per the investigator's judgment in place for the duration of the study.
For Participants Who did not Participate in NBI-921352-DEE2012:
- Written or oral pediatric assent from the participant if deemed capable of providing assent and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and for adult participants who are not capable of providing consent. Adult participants who are capable of providing consent should sign an ICF.
- Be a male or female 2 to 21 years of age, inclusive.
- Have a diagnosis of SCN8A-DEE supported by both clinical and genetic findings.
- Have on average at least 1 countable motor seizure per week and not be seizure-free for more than 20 consecutive days.
- Being treated with at least 1 other antiseizure medication (ASM), but no more than 4 ASMs.
- Have failed to achieve seizure freedom with at least 2 ASMs.
- Have a body weight of at least 10 kilograms.
Key Exclusion Criteria
For Participants Who Participated in NBI-921352-DEE2012:
- Have developed any other disorder for which the treatment takes priority over treatment of SCN8A-DEE or is likely to interfere with study treatment or impair treatment compliance.
For Participants Who did not Participate in NBI-921352-DEE2012:
- Have symptoms that would be more consistent with another epilepsy disorder such as Dravet syndrome (for example, fever-induced episodes of status epilepticus, frequent myoclonic seizures, worsening on sodium channel blockers, absence seizures with generalized spike-and-wave electroencephalogram [EEG] as the sole seizure type).
- Currently receiving cannabinoids or medical marijuana except Epidiolex/Epidyolex, unless approved by the Sponsor.
- Currently taking systemic steroids (excluding inhaled medication for asthma treatments and intranasal steroids for allergies) such as adrenocorticotropin hormone, high-dose prednisolone for epileptic spasms. If participant has received these medications in the past, they must be off these medications for at least 3 months prior to the screening visit and these drugs may not be initiated during the duration of the study. Intermittent steroids to treat non-epilepsy-related diseases (such as allergies or dermatological conditions) are not exclusionary.
- Have a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect nervous system functioning.
- Have a clinically significant medical condition or chronic disease, that in the opinion of the investigator would preclude the participant from participating in and completing the study or that could confound interpretation of study outcome.
- Have clinically significant abnormal vital signs at the screening visit, as determined by the investigator.
- Have one or more clinical laboratory test values outside the reference range, based on blood samples taken at the screening visit, that are of potential risk to the participants safety as determined by the investigator.
- Have, at the screening visit, an electrocardiogram (ECG) finding of a corrected QT interval using Fridericia's formula (QTcF) > 450 milliseconds (msec) or presence of any significant cardiac abnormality.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:NBI-921352
NBI-921352 administered for up to 164 weeks. |
Administered orally |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Number of Participants with Serious treatment-emergent adverse events (TEAEs), TEAEs Leading to Discontinuation and Fatal TEAEs
大体时间:Day 1 to Week 168
|
Day 1 to Week 168
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Percentage Change from Baseline in 28-day Seizure Frequency for Countable Motor Seizures
大体时间:Baseline, up to Week 162
|
Baseline, up to Week 162
|
合作者和调查者
调查人员
- 研究主任:Clinical Development Lead、Neurocrine Biosciences
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.